XNAS · XENE
-6.63% · -$2.59 · Vol 3.2M
After hours · updated 17:01:52 ET
Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS
$36.50
Card
Relationship Map

Follow $XENE

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $XENE by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology

snapshot unavailable for XENE. Cause unavailable.

Earnings absence reason unknown · Sentiment absence reason unknown
XENE
Xenon Pharmaceuticals Inc
Stale score · Tue Sep 22 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

40/ 100
Veridion Score
Lower range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Stale score · Tue Sep 22 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is XENE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading XENE catalysts
About Xenon Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2014
Employees
370
Country
US

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$39.51
Day high
$39.51
Day low
$36.07
Previous close
$39.09
52W high
$70.96
-48.56% from high
52W low
$36.07
1% of range
Market cap
$3.8B
EPS
$-4.5000
Beta
0.47
Shares out
96.8M
Volume
3.2M
2.09× rel vol
Avg volume
1.5M
VWAP
$36.89
Price history computed in-house
1W
-35.69%
1M
-39.73%
3M
-35.72%
1Y
-2.17%
YTD
-18.56%
SMA 50 $60.51 · below
SMA 200 $53.32 · below
52W position 1%

XENE overview

Veridion Score
40
Registered · 2026-09-22
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around XENE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading XENE Form 4 filings
Public disclosures

Congress activity in XENE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for XENE in the cached public ledger.

Federal contracts

XENE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for XENE in this window.
Lobbying spend

XENE lobbying filings, year to date.

Registered lobbying filings matched to Xenon Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for XENE in this window.
Loading news for XENE
Analyst ratings
Sovereign unlock shows live analyst consensus for XENE.
Options
Sovereign unlock shows live options positioning for XENE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.